Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in a Phase 3 lung cancer clinical trial.
Summit's partner company tested a new cancer medicine and got better results than a popular existing one in sick patients. This suggests their medicine might help people, which could make more doctors and patients interested in the company's work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.